Karolina Kozak1, Maryam Sharif-Razi2, Marya Morozova2, Erin V Gaudette2, Mera S Barr3, Zafiris J Daskalakis3, Daniel M Blumberger3, Tony P George4. 1. Addictions Division, Centre for Addiction and Mental Health (CAMH), Canada; Division of Brain and Therapeutics, Department of Psychiatry, University of Toronto, Canada; Institute of Medical Sciences, University of Toronto, Canada. Electronic address: karolina.kozak@camh.ca. 2. Addictions Division, Centre for Addiction and Mental Health (CAMH), Canada. 3. Division of Brain and Therapeutics, Department of Psychiatry, University of Toronto, Canada; Institute of Medical Sciences, University of Toronto, Canada. 4. Addictions Division, Centre for Addiction and Mental Health (CAMH), Canada; Division of Brain and Therapeutics, Department of Psychiatry, University of Toronto, Canada; Institute of Medical Sciences, University of Toronto, Canada.
Abstract
BACKGROUND: High rates of tobacco smoking and smoking cessation failure in schizophrenia may be related to prefrontal cortical dysfunction. Novel treatment options for tobacco use disorder are needed given the limited efficacy of current pharmacotherapies. Preliminary evidence suggests high-frequency repetitive transcranial magnetic stimulation (rTMS) to bilateral dorsolateral prefrontal cortex (DLPFC) may suppress tobacco craving in smokers with schizophrenia. The goal of this study was to determine effects of rTMS for tobacco craving and cognition using a short-term (3-day) human laboratory paradigm. METHODS:Bilateral active (20Hz) versus sham rTMS stimulation was administered in a counterbalanced, double-blind, cross-over design to thirteen smokers with schizophrenia and n=14 non-psychiatric smoking controls. Participants were studied at baseline (smoking satiated), after 16h of smoking abstinence, and after smoking reinstatement. Primary outcome measures included tobacco craving, withdrawal and cognition. RESULTS: Overnight abstinence produced a significant increase in tobacco craving and withdrawal, and impaired verbal memory and visuospatial working memory in both diagnostic groups; these effects were reversed with smoking reinstatement. However, active rTMS did not modify this pattern of results. Moreover, active versus sham rTMS had no significant effects on cognitive outcomes, and was not associated with significant adverse events. CONCLUSIONS: Our preliminary findings suggest that short-term rTMS administration may not be sufficient enough to modify cognition, craving, and withdrawal outcomes in smokers with schizophrenia (NCT00736710). Longer-term, controlled treatment studies examining effects of rTMS on smoking behaviors and cognition in schizophrenia are warranted.
RCT Entities:
BACKGROUND: High rates of tobacco smoking and smoking cessation failure in schizophrenia may be related to prefrontal cortical dysfunction. Novel treatment options for tobacco use disorder are needed given the limited efficacy of current pharmacotherapies. Preliminary evidence suggests high-frequency repetitive transcranial magnetic stimulation (rTMS) to bilateral dorsolateral prefrontal cortex (DLPFC) may suppress tobacco craving in smokers with schizophrenia. The goal of this study was to determine effects of rTMS for tobacco craving and cognition using a short-term (3-day) human laboratory paradigm. METHODS: Bilateral active (20Hz) versus sham rTMS stimulation was administered in a counterbalanced, double-blind, cross-over design to thirteen smokers with schizophrenia and n=14 non-psychiatric smoking controls. Participants were studied at baseline (smoking satiated), after 16h of smoking abstinence, and after smoking reinstatement. Primary outcome measures included tobacco craving, withdrawal and cognition. RESULTS: Overnight abstinence produced a significant increase in tobacco craving and withdrawal, and impaired verbal memory and visuospatial working memory in both diagnostic groups; these effects were reversed with smoking reinstatement. However, active rTMS did not modify this pattern of results. Moreover, active versus sham rTMS had no significant effects on cognitive outcomes, and was not associated with significant adverse events. CONCLUSIONS: Our preliminary findings suggest that short-term rTMS administration may not be sufficient enough to modify cognition, craving, and withdrawal outcomes in smokers with schizophrenia (NCT00736710). Longer-term, controlled treatment studies examining effects of rTMS on smoking behaviors and cognition in schizophrenia are warranted.
Authors: Karolina Kozak; Sarah S Dermody; Rachel A Rabin; Martin Zack; Mera S Barr; Rachel F Tyndale; Tony P George Journal: Schizophr Res Date: 2017-03-11 Impact factor: 4.939
Authors: Victoria C Wing; Mera S Barr; Caroline E Wass; Nir Lipsman; Andres M Lozano; Zafiris J Daskalakis; Tony P George Journal: Brain Stimul Date: 2012-07-09 Impact factor: 8.955
Authors: Daniel Kamp; Christina Engelke; Thomas Wobrock; Birgit Kunze; Wolfgang Wölwer; Georg Winterer; Christian Schmidt-Kraepelin; Wolfgang Gaebel; Berthold Langguth; Michael Landgrebe; Peter Eichhammer; Elmar Frank; Göran Hajak; Christian Ohmann; Pablo E Verde; Marcella Rietschel; Ahmed Raees; William G Honer; Berend Malchow; Thomas Schneider-Axmann; Peter Falkai; Alkomiet Hasan; Joachim Cordes Journal: Schizophr Res Date: 2017-06-01 Impact factor: 4.939
Authors: Christine E Sheffer; Warren K Bickel; Thomas H Brandon; Christopher T Franck; Darwin Deen; Luana Panissidi; Syed Amir Abdali; Jami C Pittman; Sara E Lunden; Neelam Prashad; Ria Malhotra; Antonio Mantovani Journal: Drug Alcohol Depend Date: 2017-11-04 Impact factor: 4.492
Authors: Kristi A Sacco; Angelo Termine; Aisha Seyal; Melissa M Dudas; Jennifer C Vessicchio; Suchitra Krishnan-Sarin; Peter I Jatlow; Bruce E Wexler; Tony P George Journal: Arch Gen Psychiatry Date: 2005-06
Authors: Mera S Barr; Faranak Farzan; Pablo M Rusjan; Robert Chen; Paul B Fitzgerald; Zafiris J Daskalakis Journal: Neuropsychopharmacology Date: 2009-07-15 Impact factor: 7.853
Authors: Nicholas D Henkel; Xiajoun Wu; Sinead M O'Donovan; Emily A Devine; Jessica M Jiron; Laura M Rowland; Zoltan Sarnyai; Amy J Ramsey; Zhexing Wen; Margaret K Hahn; Robert E McCullumsmith Journal: Mol Psychiatry Date: 2022-03-09 Impact factor: 13.437
Authors: Xingbao Li; Karen J Hartwell; Scott Henderson; Bashar W Badran; Kathleen T Brady; Mark S George Journal: Brain Stimul Date: 2020-06-10 Impact factor: 8.955
Authors: Ahmed A Abdelrahman; Mostafa Noaman; Mohamed Fawzy; Amira Moheb; Ahmed A Karim; Eman M Khedr Journal: Sci Rep Date: 2021-01-15 Impact factor: 4.379
Authors: Samantha Johnstone; Maryam Sorkhou; Nada Al-Saghir; Darby J E Lowe; Vaughn R Steele; Godfrey D Pearlson; David J Castle; Tony P George Journal: Front Psychiatry Date: 2022-02-14 Impact factor: 4.157
Authors: Karolina Kozak Bidzinski; Darby J E Lowe; Marcos Sanches; Maryam Sorkhou; Isabelle Boileau; Michael Kiang; Daniel M Blumberger; Gary Remington; Clement Ma; David J Castle; Rachel A Rabin; Tony P George Journal: Schizophrenia (Heidelb) Date: 2022-02-24